Study #2021-0927
Acalabrutinib for Chronic Graft-versus-Host Disease
MD Anderson Study Status
Enrolling
Treatment Agent
Acalabrutinib
Description
This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
Study phase:
Phase II
Physician name:
Amin Alousi
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-421-1842
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.